{"analyses":[{"ciLowerLimit":"0.87","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.82","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2232","paramType":"CMH ESTIMATE OF COMMON ODDS RATIO","paramValue":"1.26","statisticalMethod":"CMH ESTIMATE OF COMMON ODDS RATIO"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.7","upperLimit":"86.6","value":"82.9"},{"groupId":"OG001","lowerLimit":"75.0","upperLimit":"83.4","value":"79.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with objective response among all randomized subjects. Participants with an objective response are those participants experiencing a partial response (PR) or better, based on Independent Review Committee (IRC) assessment, as per EBMT criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to primary completion date (approximately 8 years)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}